Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance.

Abstract:

:Sertindole is a novel atypical antipsychotic, which has shown efficacy in the treatment of positive and negative symptoms of schizophrenia in phase II and III studies. Furthermore, these studies have demonstrated tolerability and a favourable side-effect profile. In contrast to classical antipsychotics, sertindole was not associated with extrapyramidal symptoms (EPS). We report drug surveillance data in 34 comorbid and comedicated sertindole treated patients suffering from different psychotic disorders. The drug surveillance consisted of two distinct phases: inpatient treatment and outpatient follow-up. Clinical global impression (severity and improvement of illness), psychotic symptoms, side-effects, and blood parameters have been carefully documented. With special respect to cardiac safety electrocardiograms (ECGs) have been recorded twice (during sertindole treatment and during treatment with an antipsychotic different from sertindole). Recommended ECG-parameters for assessment of the proarrhythmic risk of a drug have been calculated (QTc-, QTc2-interval; QT-, QTc-dispersion). The majority of patients (n = 29) have been treated previously with several typical and/or atypical antipsychotics. We observed a clinical response to sertindole treatment in 29 patients (85%). Both positive and negative symptoms improved with sertindole and no severe side-effects have been documented. EPS occurred at placebo level. A mean QTc-interval prolongation of 19.7 ms (4.7%) has been detected. None of the patients developed clinical or electrocardiographic evidence of cardiac dysrhythmia during sertindole treatment, or other clinical evidence of cardiac abnormalities. In summary, sertindole did show efficacy for positive and negative symptoms together with a favourable side-effect profile. No evidence for an increased proarrhythmic risk has been found.

authors

Pezawas L,Quiner S,Moertl D,Tauscher J,Barnas C,Küfferle B,Wolf R,Kasper S

doi

10.1097/00004850-200015040-00003

subject

Has Abstract

pub_date

2000-07-01 00:00:00

pages

207-14

issue

4

eissn

0268-1315

issn

1473-5857

journal_volume

15

pub_type

杂志文章
  • The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study.

    abstract::The aim of this study was to evaluate flexibly dosed brexpiprazole for early-episode schizophrenia through the assessment of efficacy, social functioning, and tolerability. This was an exploratory, 16-week, open-label, flexible-dose (1, 2, 3, or 4 mg/day; target dose 3 mg/day) study in outpatients with early-episode s...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0000000000000140

    authors: Malla A,Ota A,Nagamizu K,Perry P,Weiller E,Baker RA

    更新日期:2016-11-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • Amantadine as augmentation therapy in the management of treatment-resistant depression.

    abstract::Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionall...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200303000-00005

    authors: Stryjer R,Strous RD,Shaked G,Bar F,Feldman B,Kotler M,Polak L,Rosenzcwaig S,Weizman A

    更新日期:2003-03-01 00:00:00

  • Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.

    abstract::The objective of this study was to examine the safety and tolerability of duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, in a large cohort of elderly patients with major depressive disorder. Data were pooled from 8-week and 12-week, double-blind, randomized, placebo-controlled trials of dulox...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/YIC.0b013e32835b09cd

    authors: Oakes TM,Katona C,Liu P,Robinson M,Raskin J,Greist JH

    更新日期:2013-01-01 00:00:00

  • Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression.

    abstract::Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-bl...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000016

    authors: Khan A,Sambunaris A,Edwards J,Ruth A,Robinson DS

    更新日期:2014-03-01 00:00:00

  • A novel approach to rater training and certification in multinational trials.

    abstract::Clinical trials are becoming increasingly international in scope. Global studies pose unique challenges in training and calibrating raters owing to language and cultural differences. Recent findings that poorly conducted interviews reduce study power, makes attention to raters' clinical skills critical. In this study,...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3280803dad

    authors: Jeglic E,Kobak KA,Engelhardt N,Williams JB,Lipsitz JD,Salvucci D,Bryson H,Bellew K

    更新日期:2007-07-01 00:00:00

  • Rationalizing antidepressants for elderly people.

    abstract::A rational approach to the use of antidepressants in the elderly must consider the evidence as to whether such treatment is efficacious (in controlled trials) and effective in clinical practice. Effective treatment of depression depends on its detection, and the subsequent initiation and continuation of adequate treat...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199503001-00007

    authors: Katona C

    更新日期:1995-03-01 00:00:00

  • Continuity of treatment with benzodiazepines in dementia patients: an analysis of German health insurance claims data.

    abstract::Long-term treatment with benzodiazepines (BZD) should be avoided in dementia patients because of an increased risk of adverse events. We evaluated how continuously dementia patients were prescribed BZD over 12 months. For this observational study, we used claims data from a large German public sickness fund for 2014 a...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000230

    authors: Hessmann P,Jan Zeidler,Neubauer S,Abdel-Hamid M,Stahmeyer J,Eberhard S,Wolff-Menzler C,Wiltfang J,Kis B

    更新日期:2018-09-01 00:00:00

  • Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder.

    abstract::Since the discovery that clomipramine was effective in the treatment of obsessive-compulsive disorder (OCD), trials of several different medications for OCD have been published. The question of which agent, if any, is the medication of choice in OCD is of real clinical concern. Published clinical trials were collected...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-199503000-00002

    authors: Stein DJ,Spadaccini E,Hollander E

    更新日期:1995-03-01 00:00:00

  • Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?

    abstract::The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Ashford JJ

    更新日期:1995-01-01 00:00:00

  • Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline.

    abstract::A total of 101 patients entered a double-blind, parallel-group study in general practice, comparing the efficacy and tolerability of paroxetine and amitriptyline in elderly depressed patients. All patients received placebo for 1 week followed by active therapy for a total of 6 weeks. Medication was randomly allocated,...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199206004-00009

    authors: Hutchinson DR,Tong S,Moon CA,Vince M,Clarke A

    更新日期:1992-06-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Extended-release quetiapine fumarate (quetiapine XR) versus risperidone in the treatment of depressive symptoms in patients with schizoaffective disorder or schizophrenia: a randomized, open-label, parallel-group, flexible-dose study.

    abstract::Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperido...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0000000000000017

    authors: Di Fiorino M,Montagnani G,Trespi G,Kasper S

    更新日期:2014-05-01 00:00:00

  • Antidepressant interactions with warfarin.

    abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199803000-00006

    authors: Duncan D,Sayal K,McConnell H,Taylor D

    更新日期:1998-03-01 00:00:00

  • Abnormal correlation between serum leptin levels and body mass index may predict metabolic dysfunction irrespective of the psychopharmacological treatment.

    abstract::In an earlier study, we found a similar frequency of individuals with an abnormal correlation between serum leptin levels and body mass index (BMI) (outliers above or below the 95% confidence interval in the regression line) during treatment with antipsychotic drugs (n=301), other psychotropic drugs (n=65), and drug-f...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e328342ce47

    authors: Marquina D,Peña R,Fernández E,Baptista T

    更新日期:2011-05-01 00:00:00

  • Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications.

    abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283400cd3

    authors: Kim SH,Reaven G,Lindley S

    更新日期:2011-01-01 00:00:00

  • Antidepressant-induced hypomania in obsessive-compulsive disorder.

    abstract::Out of ten consecutive patients with DSM-III-R obsessive-compulsive disorder without any previous history of bipolarity, three patients showed antidepressant-induced hypomania (clomipramine, one patient; fluvoxamine, two patients) within the first 5 to 8 weeks of the drug treatment. These data support the previous res...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199609000-00008

    authors: Rihmer Z,Barsi J,Belsõ N,Pestality P,György S

    更新日期:1996-09-01 00:00:00

  • Prophylactic efficacy of lithium, valproic acid, and carbamazepine in the maintenance phase of bipolar disorder: a naturalistic study.

    abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000097

    authors: Peselow ED,Clevenger S,IsHak WW

    更新日期:2016-07-01 00:00:00

  • Agitation in the demented elderly: a role for benzodiazepines?

    abstract::"Agitation" is a term that is used to describe a wide range of dysfunctional behaviours in geriatric populations. The term is so widely used that in many cases it loses clinical meaning and therefore a more restricted use of the term is suggested. When patients with agitation are identified it is important to look for...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199100630-00002

    authors: Ancill RJ,Carlyle WW,Liang RA,Holliday SG

    更新日期:1991-01-01 00:00:00

  • Adverse effects of antipsychotic drugs.

    abstract::The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199501005-00005

    authors: Whitworth AB,Fleischhacker WW

    更新日期:1995-01-01 00:00:00

  • Socioeconomic factors influencing antipsychotic prescription for schizophrenia inpatients in China: a cross-sectional study.

    abstract::Medication is critical in schizophrenia therapy, and prescription patterns have changed considerably over the past 20 years in China. This study attempts to evaluate the prescription patterns of antipsychotics for inpatients with schizophrenia in China and to identify factors influencing these patterns. Claims data of...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000024

    authors: Xue Q,Xiong X,Feng Y,Yao L,Chen S,Xiang L

    更新日期:2014-09-01 00:00:00

  • 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.

    abstract::On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000321

    authors: Yousefzadeh F,Sahebolzamani E,Sadri A,Mortezaei A,Aqamolaei A,Mortazavi SH,Shalbafan MR,Ghaffari S,Alikhani R,Mousavi SB,Naderi S,Shamabadi A,Jalilevand S,Akhondzadeh S

    更新日期:2020-09-01 00:00:00

  • Iloperidone-induced retrograde ejaculation.

    abstract::This case series describes the development of retrograde ejaculation with the antipsychotic iloperidone. Iloperidone is a relatively new antipsychotic and has a strong α-1 receptor antagonism, which may explain this rare adverse effect. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e32835e9112

    authors: Freeman SA

    更新日期:2013-05-01 00:00:00

  • ADDH and methylphenidate responders: effects on behavior controlled by complex reinforcement schedules.

    abstract::One of the most effective treatments for children with Attention Deficit Disorder with Hyperactivity (ADDH) has been the prescription of methylphenidate (MPH). While laboratory-based evidence indicates that MPH effects may be rate-dependent, little is known about changes evinced in operant behavior controlled by compl...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198810000-00006

    authors: DuPaul GJ,Rapport MD,Vyse SA

    更新日期:1988-10-01 00:00:00

  • Effectiveness of parental training, methylphenidate treatment, and their combination on academic achievements and behavior at school of children with attention-deficit hyperactivity disorder.

    abstract::This study aimed to compare the effectiveness of parental training (PT), methylphenidate treatment (MPH), and the combination of PT and MPH treatment (PT/MPH) on school achievements in children with attention-deficit hyperactivity disorder (ADHD). Twenty eight ADHD patients (age: 10.1±1.11 years) were divided into thr...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验

    doi:10.1097/YIC.0000000000000218

    authors: Golubchik P,Hamerman H,Manor I,Peskin M,Weizman A

    更新日期:2018-07-01 00:00:00

  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder.

    abstract::Characteristic response patterns are described for two antidepressant drugs and placebo in post-traumatic stress disorder. Early onset and steady improvement occurred on a global rating scale for both drugs and placebo in those who ultimately met responder criteria at the end of treatment. In certain cases, the magnit...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,评审

    doi:10.1097/00004850-199711000-00001

    authors: Davidson JR,Malik ML,Sutherland SN

    更新日期:1997-11-01 00:00:00

  • Response to venlafaxine in a previously antidepressant treatment-resistant combat veteran with post-traumatic stress disorder.

    abstract::Post-traumatic stress disorder (PTSD) is frequently treated with antidepressant medications, especially the newer selective serotonergic antidepressants which have documented efficacy in PTSD. Analogous to depression, however, some PTSD patients may not have a satisfactory response to these agents. This case report de...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199809000-00008

    authors: Hamner MB,Frueh BC

    更新日期:1998-09-01 00:00:00

  • New aspects in the treatment of depression.

    abstract::Because of the limitations in efficacy and safety of the older tricyclic antidepressants (TCA) and monoamine oxidase inhibitors (MAOI) a number of new approaches have been made in recent years to the treatment of depression to obtain more effective, more rapidly acting, better tolerated and safer drugs. One tactic has...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199206005-00004

    authors: Silverstone T

    更新日期:1992-06-01 00:00:00

  • A detailed longitudinal analysis on the use of naltrexone in the treatment of bulimia.

    abstract::In accord with our auto-addiction opioid model, naltrexone was previously reported to be effective in the treatment of bulimia in a controlled double-blind clinical trial with a randomized cross-over design. This is a detailed longitudinal analysis over a 16 month period of one subject from that study. Attenuation in ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199510030-00006

    authors: Marrazzi MA,Kinzie J,Luby ED

    更新日期:1995-09-01 00:00:00

  • Depression in the community: the first pan-European study DEPRES (Depression Research in European Society).

    abstract::DEPRESS (Depression Research in European Society) is the first large pan-European survey of depression in the community. A total of 13359 of the 78463 adults who participated in screening interviews across six countries were identified as suffering from depression, a 6-month prevalence of 17%. Major depression account...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:

    authors: Lépine JP,Gastpar M,Mendlewicz J,Tylee A

    更新日期:1997-01-01 00:00:00